A kidney-tonifying, yang-strengthening and anti-fatigue medicinal composition and preparation method thereof

Through the combination of Artemisia african and geranium geranium extract and a variety of Chinese medicinal materials, a pharmaceutical composition for kidney-tonifying and yang-resistant and anti-fatigue was prepared, which solved the problems of fatigue and sexual dysfunction in the prior art and achieved safety , effective therapeutic effects, and improve the production efficiency and cost-effectiveness of drugs.

CN118787676BActive Publication Date: 2024-11-08SHENZHEN ANMEIXIN BIO-PHARM TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411265090.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-09-10
Publication Date
2024-11-08
Estimated Expiration
2044-09-10

AI Technical Summary

Technical Problem

The prior art cannot effectively solve the problems of fatigue and male sexual dysfunction, especially penile erectile dysfunction and sexual desire reduction, and the safety and side effects of drugs that nourish kidneys and strengthen yang.

Method used

Using the composition of Artemisia african and geranium geranium extract and a variety of traditional Chinese medicinal materials, a pharmaceutical composition that nourishes kidneys and strengthens erectile dysfunction and anti-fatigue is prepared through specific ratios and preparation methods, for the production of oral preparations, combined with Ethanol-isopropanol-water mixed solvent extraction and freeze-drying technology ensures the safety and stability of the drug.

Benefits of technology

The composition significantly improves back pain, soreness and softness of limbs, impotence and premature ejaculation, low libido and memory loss, has significant anti-fatigue and erotic effects, and has simple preparation technology, high production efficiency, low cost, and has wide application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
Patent Text Reader

Abstract

The invention discloses a kidney-tonifying, yang-strengthening and anti-fatigue pharmaceutical composition and a preparation method. The composition comprises ginseng, sika deer penis, red deer antler, sea cucumber, oyster, polygonatum, wolfberry, maca, yam, epimedium, Cistanche deserticola, cordyceps militaris, eucommia bark, okra, silkworm chrysanthemum, dodder seed, rosa laevigata, acanthopanax senticosus, rhodiola rosea, royal jelly, pumpkin seed oil, lycopene, pyrroloquinoline quinone, taurine, γ-aminobutyric acid, Artemisia afra Jacq.ex Willd. and Pelargonium sidoides extract. The composition has a reasonable proportion, is safe, has no toxic side effects, is easy to take and carry, can tonify the kidney and strengthen yang, resist fatigue, and has significant effects on backache, sore limbs, impotence and premature ejaculation, low libido and memory loss. The oral pharmaceutical preparation containing the composition has a simple preparation process, stable and reliable drug performance, high production efficiency, low production cost, and has broad application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the biological and medical fields, and specifically relates to a kidney-tonifying, yang-strengthening and anti-fatigue medicinal composition, a polypeptide with a new structure, and their medical uses. Background Art

[0002] Fatigue is a common nonspecific symptom with a wide variety of causes, including various acute or chronic physical illnesses, mental illnesses, drug toxicity, etc. Fatigue usually includes difficulty or inability to start activities (subjective weakness), reduced ability to maintain activities (easy fatigability), or difficulty concentrating, memory loss, and poor emotional stability (mental fatigue).

[0003] As age increases, the incidence of male sexual dysfunction increases, including erectile dysfunction, decreased libido, and ejaculation disorders. Abnormal penile erections may be caused by abnormal blood vessels and nerves that cause blood to accumulate in the erectile tissue (corpora cavernosa) of the penis. Other possible causes include hormonal disorders, abnormal penile structure, use of certain drugs, and psychological problems. The most common specific causes are atherosclerosis, diabetes, complications of prostate surgery, and the effects of certain drugs.

[0004] There is still an urgent need for drugs that can nourish the kidneys, strengthen yang and fight fatigue. Summary of the invention

[0005] The present invention provides a kidney-tonifying, yang-strengthening and anti-fatigue pharmaceutical composition and a preparation method thereof. The composition has reasonable proportions of various components, is safe, has no toxic side effects, and is convenient for patients to take and carry; it can tonify the kidney and strengthen yang, resist fatigue, and has significant effects on back pain, sore limbs, impotence and premature ejaculation, low libido, and memory loss. In addition, the preparation process of an oral pharmaceutical preparation containing the composition is simple, the drug performance is stable and reliable, the production efficiency is high, the production cost is low, and it has broad application prospects.

[0006] In a first aspect of the present invention, an extract is provided, characterized in that the preparation method of the extract comprises the following steps:

[0007] Take the whole plant of Artemisia africana and the whole plant of Pelargonium sutchuenensis, grind them into powder to obtain powders of the two plant raw materials;

[0008] Take equal weight of powder and mix them evenly; add ethanol-isopropanol-water mixed solvent, wherein the volume ratio of ethanol, isopropanol and water is (2-4): (0.8-1.2): (0.8-1.2), heat to 40-60 degrees Celsius for extraction, filter after cooling, and freeze-dry the filtrate to obtain the extract.

[0009] The Latin name of the African Artemisia described in the present invention is Artemisia afra Jacq. ex Willd.; the Latin name of the Pelargonium sidoides is Pelargonium sidoides.

[0010] In some embodiments of the present invention, the method for preparing the extract comprises the following steps:

[0011] Take the whole plant of Artemisia africana and the whole plant of Pelargonium sutchuenensis, wash them with water, air-dry them at room temperature, and grind them into fine powder with an average particle size of 900 microns to obtain the two plant raw materials;

[0012] Take equal masses of the two fine powders and mix them to obtain a mixed powder; add an ethanol-isopropanol-water mixed solvent with a mass 10 times that of the mixed powder, wherein the volume ratio of the ethanol, isopropanol and water is 3:1:1; heat to 50° C. and stir at a rate of 100 rpm for 5 hours, filter after cooling, and freeze-dry the filtrate to obtain the extract.

[0013] In some embodiments of the present invention, the extract is the extract AAPS-01 as described in Example 1, and the preparation method of the extract is as described in Example 1.

[0014] In a second aspect of the present invention, a composition is provided, characterized in that the preparation method of the composition comprises the following steps:

[0015] Take 10-85 parts by weight of ginseng, 10-90 parts by weight of sika deer penis, 20-95 parts by weight of red deer antler, 15-90 parts by weight of sea cucumber, 20-95 parts by weight of oyster, 20-90 parts by weight of polygonatum, 25-110 parts by weight of wolfberry, 10-90 parts by weight of maca, 10-95 parts by weight of yam, 25-100 parts by weight of epimedium, 10-85 parts by weight of Cistanche deserticola, 0.5-6 parts by weight of Cordyceps militaris, 15-90 parts by weight of Eucommia ulmoides, 20-95 parts by weight of okra, 10-90 parts by weight of silkworm chrysalis, and 10-90 parts by weight of ginseng. 0 parts by weight, 25-100 parts by weight of Cuscuta seeds, 25-100 parts by weight of Rosa laevigata, 25-100 parts by weight of Acanthopanax senticosus, 25-100 parts by weight of Rhodiola rosea, 25-100 parts by weight of royal jelly, 25-95 parts by weight of pumpkin seed oil, 20-90 parts by weight of lycopene, 20-90 parts by weight of pyrroloquinoline quinone, 10-90 parts by weight of taurine, 10-95 parts by weight of gamma-aminobutyric acid, and 50 parts by weight of extracts of Artemisia africana and Pelargonium sphenanthera; mix well to obtain the composition;

[0016] The preparation method of the extracts of Artemisia africana and Pelargonium sidoides is as described in the first aspect.

[0017] In some embodiments of the present invention, the mass ratio of the raw materials is as follows:

[0018] 50 parts by weight of ginseng powder, 50 parts by weight of sika deer penis powder, 50 parts by weight of red deer antler powder, 50 parts by weight of sea cucumber powder, 50 parts by weight of oyster powder, 50 parts by weight of polygonatum powder, 50 parts by weight of wolfberry powder, 50 parts by weight of maca powder, 50 parts by weight of yam powder, 50 parts by weight of epimedium powder, 50 parts by weight of Cistanche powder, 5 parts by weight of Cordyceps militaris powder, 50 parts by weight of Eucommia powder, 50 parts by weight of okra powder, 50 parts by weight of silkworm pupa powder, 50 parts by weight of Cuscuta powder, 50 parts by weight of Rosa laevigata powder, 50 parts by weight of Acanthopanax powder, 50 parts by weight of Rhodiola rosea powder, 50 parts by weight of royal jelly, 50 parts by weight of pumpkin seed oil, 20 parts by weight of lycopene, 20 parts by weight of pyrroloquinoline quinone, 10 parts by weight of taurine, 10 parts by weight of γ-aminobutyric acid, and 50 parts by weight of extracts of Artemisia africana and Pelargonium angustifolia.

[0019] In some embodiments of the present invention, the ginseng is raw sun-dried ginseng, dried roots and rhizomes.

[0020] In some embodiments of the present invention, the sika deer whip is a dry whip.

[0021] In some embodiments of the present invention, the velvet antler is the dried velvet antler of Cervus elaphus.

[0022] In some embodiments of the present invention, the sea cucumber is a dried Apostichopus japonicus.

[0023] In some embodiments of the invention, the oyster is the dried meat of the long oyster.

[0024] In some embodiments of the present invention, the polygonatum is the dried rhizome of polygonatum yunnanensis.

[0025] In some embodiments of the present invention, the wolfberry is a dried fruit.

[0026] In some embodiments of the present invention, the maca is a dried rhizome.

[0027] In some embodiments of the present invention, the yam is a dried tuber of Dioscorea zingiberensis.

[0028] In some embodiments of the present invention, the epimedium is the dried stems and leaves of Epimedium pubescens.

[0029] In some embodiments of the present invention, the Cistanche deserticola is a dried stem.

[0030] In some embodiments of the present invention, the Cordyceps militaris is a dried stroma.

[0031] In some embodiments of the present invention, the Eucommia ulmoides is dried bark.

[0032] In some embodiments of the present invention, the okra is a dried immature young fruit.

[0033] In some embodiments of the present invention, the silkworm pupae are dried silkworm pupae.

[0034] In some embodiments of the present invention, the dodder seeds are dried mature seeds of dodder.

[0035] In some embodiments of the present invention, the Rosa laevigata fruit is a dried mature fruit.

[0036] In some embodiments of the present invention, the Acanthopanax senticosus is a dried rhizome.

[0037] In some embodiments of the present invention, the Rhodiola rosea is a dried rhizome.

[0038] In some embodiments of the present invention, the royal jelly is a freeze-dried product of a milky white jelly secreted by the pharyngeal gland and post-pharyngeal gland of worker bees of the Chinese honey bee.

[0039] In some embodiments of the present invention, the pumpkin seed oil is produced by cold pressing.

[0040] In some embodiments of the present invention, a composition is provided, characterized in that the preparation method of the composition comprises the following steps:

[0041] Take raw sun-dried ginseng, sika deer penis, velvet antler of Northeast red deer, imitation sea cucumber, long oyster meat, rhizome of polygonatum yunnanensis, fruit of wolfberry, rhizome of maca, tuber of yam, stem and leaf of epimedium pubescens, stem of cistanche deserticola, fruiting body of cordyceps militaris, bark of eucommia bark, immature tender fruit of okra, silkworm pupa, dodder seed, rosa laevigata fruit, rhizome of acanthopanax senticosus and rhodiola rosea; wash them with water, air-dry them at room temperature, and grind them into powder with an average particle size of 900 μm to obtain powder of each raw material;

[0042] Take 50g of ginseng powder, 50g of sika deer penis powder, 50g of red deer antler powder, 50g of sea cucumber powder, 50g of oyster powder, 50g of polygonatum powder, 50g of wolfberry powder, 50g of maca powder, 50g of yam powder, 50g of epimedium powder, 50g of Cistanche powder, 5g of Cordyceps militaris powder, 50g of Eucommia powder, 50g of okra powder, 50g of silkworm pupa powder, 50g of Cuscuta powder, 50g of Rosa laevigata powder, 50g of Acanthopanax powder, and 50g of Rhodiola rosea powder obtained as described above; then add 50g of worker bee royal jelly of Apis cerana cerasifera, 50g of pumpkin seed oil, 20g of lycopene, 20g of pyrroloquinoline quinone, 10g of taurine, 10g of γ-aminobutyric acid, and 50g of extracts of Artemisia africana and Pelargonium angustifolia; mix well to obtain the composition;

[0043] The preparation method of the extract of Artemisia africana and Pelargonium stenoticum is as follows: take the whole plant of Artemisia africana and the whole plant of Pelargonium stenoticum, wash them with water respectively, air-dry them at room temperature, grind them to an average particle size of 900 microns, take 50g of Artemisia africana powder and 50g of Pelargonium stenoticum powder, mix them evenly, add 1kg of ethanol-isopropanol-water mixed solvent, and the volume ratio of ethanol, isopropanol and water is 3:1:1; heat to 50°C and stir at a rate of 100 rpm for 5 hours, filter after cooling, and freeze-dry the filtrate to obtain the extract of Artemisia africana and Pelargonium stenoticum;

[0044] The Latin name of the African Artemisia is Artemisia afra Jacq. ex Willd.; the Latin name of the Pelargonium sidoides is Pelargonium sidoides.

[0045] In some embodiments of the present invention, the composition is the composition L-AAPS-a described in Example 2, and the preparation method of the composition is as described in Example 2.

[0046] In some embodiments of the invention, the composition is a pharmaceutical composition.

[0047] In the third aspect of the present invention, there is provided use of the extract according to the first aspect of the present invention or the composition according to the second aspect of the present invention in tonifying the kidney, strengthening yang or resisting fatigue.

[0048] In some embodiments of the present invention, there is provided use of the extract according to the first aspect of the present invention in tonifying the kidney, strengthening yang or resisting fatigue.

[0049] In some embodiments of the present invention, there is provided use of the composition according to the second aspect of the present invention in tonifying the kidney and strengthening yang or resisting fatigue.

[0050] In some embodiments of the present invention, the application is not a method for diagnosis or treatment of a disease.

[0051] In a fourth aspect of the present invention, there is provided use of the extract as described in the first aspect of the present invention or the composition as described in the second aspect of the present invention in the preparation of an anti-fatigue drug, a drug for improving erectile dysfunction or a drug for enhancing sexual performance.

[0052] In some embodiments of the present invention, there is provided use of the extract according to the first aspect of the present invention in the preparation of an anti-fatigue drug, a drug for improving erectile dysfunction, or a drug for enhancing sexual performance.

[0053] In some embodiments of the present invention, there is provided use of the extract according to the first aspect of the present invention in the preparation of an anti-fatigue drug.

[0054] In some embodiments of the present invention, there is provided use of the extract according to the first aspect of the present invention in the preparation of a medicament for improving erectile dysfunction.

[0055] In some embodiments of the present invention, there is provided use of the extract according to the first aspect of the present invention in the preparation of a drug for enhancing sexual performance.

[0056] In some embodiments of the present invention, there is provided use of the composition according to the second aspect of the present invention in the preparation of an anti-fatigue drug, a drug for improving erectile dysfunction, or a drug for enhancing sexual performance.

[0057] In some embodiments of the present invention, there is provided use of the composition according to the second aspect of the present invention in the preparation of an anti-fatigue drug.

[0058] In some embodiments of the present invention, there is provided use of the composition according to the second aspect of the present invention in the preparation of a medicament for improving erectile dysfunction.

[0059] In some embodiments of the present invention, there is provided use of the composition according to the second aspect of the present invention in the preparation of a drug for enhancing sexual performance.

[0060] In the fifth aspect of the present invention, a pharmaceutical preparation is provided, characterized in that the pharmaceutical preparation comprises the extract as described in the first aspect of the present invention or the composition as described in the second aspect of the present invention.

[0061] In some embodiments of the present invention, a pharmaceutical preparation is provided, characterized in that the pharmaceutical preparation comprises the extract as described in the first aspect of the present invention.

[0062] In some embodiments of the present invention, a pharmaceutical preparation is provided, characterized in that the pharmaceutical preparation comprises the composition as described in the second aspect of the present invention.

[0063] In some embodiments of the present invention, the pharmaceutical preparation is an oral dosage form.

[0064] In some embodiments of the present invention, the pharmaceutical preparation is an oral dosage form, and the oral dosage form is a tablet, a capsule, a granule, a pill or an oral liquid.

[0065] In a sixth aspect of the present invention, a method for preparing a pharmaceutical preparation is provided, characterized in that the preparation method comprises the following steps:

[0066] The composition as described in the second aspect of the present invention is sterilized and an oral preparation is prepared by an oral dosage form process.

[0067] In some embodiments of the present invention, the oral preparation is a tablet, a capsule, a granule, a pill or an oral solution.

[0068] In some embodiments of the present invention, a method for preparing a pharmaceutical preparation is provided, characterized in that the preparation method comprises the following steps:

[0069] The composition according to the second aspect of the present invention is sterilized by irradiation, granulated, dried and sized to obtain pharmaceutical composition granules.

[0070] In some embodiments of the present invention, a method for preparing a pharmaceutical preparation is provided, characterized in that the preparation method comprises the following steps:

[0071] The composition according to the second aspect of the present invention is sterilized by irradiation, granulated, dried, and sized to obtain pharmaceutical composition granules;

[0072] The particles of the pharmaceutical composition are mixed with pharmaceutically acceptable excipients and then filled into capsules, or the particles of the pharmaceutical composition are directly filled into capsules to obtain hard capsules.

[0073] In some embodiments of the present invention, the granulation method is to add 65%-75% ethanol in a volume fraction of 3%-6% by weight to the sterilized mixture to make a soft material and then granulate it through a 10-16 mesh sieve.

[0074] In some embodiments of the present invention, the drying temperature is 50-70° C. and the drying time is 2-4 h.

[0075] In some embodiments of the present invention, the sterilization is radiation sterilization, and the environment of the radiation sterilization is: cobalt-60 radiation sterilization, and the radiation dose is greater than 0 KGY and not more than 6 KGY.

[0076] In the seventh aspect of the present invention, a polypeptide is provided, characterized in that the amino acid sequence of the polypeptide is shown in SEQ ID NO: 1.

[0077] In an eighth aspect of the present invention, a use of a polypeptide is provided, characterized in that:

[0078] The amino acid sequence of the polypeptide is shown in SEQ ID NO: 1;

[0079] The use is to prepare anti-fatigue drugs, drugs for improving erectile dysfunction or drugs for strengthening male potency.

[0080] In some embodiments of the present invention, the use is for preparing an anti-fatigue drug.

[0081] In some embodiments of the present invention, the use is for preparing a medicament for improving erectile dysfunction.

[0082] In some embodiments of the present invention, the use is for preparing a drug for enhancing sexual performance. DETAILED DESCRIPTION

[0083] The present disclosure is further illustrated by way of examples below, but the present disclosure is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are selected according to conventional methods and conditions, or according to the product instructions. Unless otherwise specified, the reagents and raw materials used in the present disclosure are all commercially available.

[0084] Example 1. Preparation of extract

[0085] The whole plant of Artemisia afra Jacq. ex Willd. and the whole plant of Pelargonium sidoides available on the market were washed with water, air-dried at room temperature, and crushed to an average particle size of 900 microns to obtain fine powder of each plant raw material.

[0086] Take 50 g of Artemisia africana powder and 50 g of Pelargonium sutchuenensis powder, mix them evenly; add 1 kg of ethanol-isopropanol-water mixed solvent (the volume ratio of ethanol, isopropanol and water is 3:1:1), heat to 50°C and stir at 100 rpm for 5 hours, filter after cooling, and freeze-dry the filtrate to obtain 15.0 g of solid powder extract AAPS-01.

[0087] Take 50 g of Artemisia africana powder and 50 g of Pelargonium sutchuenensis powder, mix them evenly; add 1 kg of ethanol-water mixed solvent (the volume ratio of ethanol to water is 4:1), heat to 50 ° C and stir at 100 rpm for 5 hours, filter after cooling, and freeze-dry the filtrate to obtain 16.8 g of solid powder extract AAPS-02.

[0088] Example 2. Preparation of the composition

[0089] Take ginseng (raw sun-dried ginseng, dried roots and rhizomes), sika deer whip (dried whip), red deer antler (dried antler of northeastern red deer), sea cucumber (dried imitation sea cucumber), oyster (dried meat of long oyster), polygonatum (dried rhizomes of Yunnan polygonatum), wolfberry (dried fruit), maca (dried rhizomes), yam (dried tubers of Dioscorea), epimedium (dried stems and leaves of Epimedium pubescens), Cistanche deserticola (dried stems), Cordyceps militaris (dried fruiting bodies), Eucommia ulmoides (dried bark), okra (dried immature young fruits), silkworm pupae (dried silkworm pupae), dodder seed (dried mature seeds of dodder), Rosa laevigata (dried mature fruits), Acanthopanax senticosus (dried rhizomes), and Rhodiola rosea (dried rhizomes); wash them with water respectively, air-dry them at room temperature, and grind them to an average particle size of 900 microns to obtain powders of each raw material.

[0090] Take 50g of ginseng powder obtained as above, 50g of sika deer penis powder, 50g of red deer antler powder, 50g of sea cucumber powder, 50g of oyster powder, 50g of polygonatum powder, 50g of wolfberry powder, 50g of maca powder, 50g of yam powder, 50g of epimedium powder, 50g of Cistanche powder, 50g of Cordyceps sinensis powder, 50g of Eucommia powder, 50g of okra powder, 50g of silkworm pupa powder, 50g of Cuscuta powder, 50g of Rosa laevigata powder, 50g of Acanthopanax senticosus powder, and 50g of Rhodiola rosea powder. 50g of Tianfen; then add royal jelly (a freeze-dried product of the milky white glue secreted by the pharyngeal gland and postpharyngeal gland of worker bees of Apis cerana) 50g, pumpkin seed oil (cold-pressed) 50g, lycopene 20g, pyrroloquinoline quinone 20g, taurine 10g, γ-aminobutyric acid 10g, and 50g of extracts of Artemisia africana and Pelargonium angustifolia (AAPS-01); mix well to obtain a solid powder composition L-AAPS-a.

[0091] Take 50g of ginseng powder obtained as above, 50g of sika deer penis powder, 50g of red deer antler powder, 50g of sea cucumber powder, 50g of oyster powder, 50g of polygonatum powder, 50g of wolfberry powder, 50g of maca powder, 50g of yam powder, 50g of epimedium powder, 50g of Cistanche powder, 50g of Cordyceps sinensis powder, 50g of Eucommia powder, 50g of okra powder, 50g of silkworm pupa powder, 50g of Cuscuta australis powder, 50g of Rosa laevigata powder 0g, 50g of Acanthopanax powder, 50g of Rhodiola rosea powder; then add 50g of royal jelly (a freeze-dried product of the milky white glue secreted by the pharyngeal glands and postpharyngeal glands of worker bees of Apis cerana), 50g of pumpkin seed oil (cold-pressed), 20g of lycopene, 20g of pyrroloquinoline quinone, 10g of taurine, and 10g of γ-aminobutyric acid; mix well to obtain a solid powder composition L-AAPS-b.

[0092] Example 3: Anti-fatigue activity test

[0093] Take male SPF healthy KM mice, weighing 37-39g. The mice were randomly divided into 12 groups, each group was a drug group, a blank control group and a positive control group. The drug group was given an aqueous dispersion of the extract or composition described in Example 1 or Example 2 at a concentration of 10mg / mL. The positive control group was given Red Bull Vitamin Functional Drink, and the blank control group was given normal saline at a concentration of 10mg / mL. 0.2mL was given for every 10g of body weight, and the gavage method was adopted. The drug was continuously administered for 30 days. The exhaustive swimming time of the mice was measured on the 31st day, and the changes in indicators such as urea nitrogen and glycogen content in the blood were tested on the 32nd day.

[0094] Weighted swimming test: The mouse tail is loaded with a lead wire (the weight of the lead wire is 6% of the mouse body weight), and the mouse is placed in a 40cm×60cm×40cm pool for swimming, with a water depth of 30cm and a water temperature of 30℃±0.5℃. The time from the start of swimming to exhaustion (the mouse cannot float to the surface after sinking for 10s) is recorded with a stopwatch as the mouse's exhaustive swimming time. The results are averaged.

[0095] Liver glycogen and serum urea nitrogen content detection experiment: After the exhaustive swimming time of mice was measured on the 31st day, the mice were allowed to rest for at least 24 hours and fed normally. On the 32nd day, the mice were placed in water with a depth of 30 cm and a water temperature of 30℃±0.5℃ to swim (without weight), the pool was 40cm×60cm×40cm, and they swam without weight for 90 minutes. After resting for 60 minutes, the mice were killed, the livers were removed, and 200 mg was accurately weighed. The anthrone method was used to determine the liver glycogen content of the mice. The results were averaged.

[0096] The exhausted swimming time and liver glycogen content of the positive control group and the four experimental groups were better than those of the blank control group, with statistically significant differences (P<0.01). The exhausted swimming time and liver glycogen content of the L-AAPS-a group were better than those of the other groups (P<0.05), showing the synergistic effect of the extracts of Artemisia africana and Pelargonium angustifolium (AAPS-01) and other components.

[0097] The exhausted swimming time and liver glycogen content of the AAPS-01 group were better than those of the AAPS-02 group (P<0.05), indicating the influence of different extraction solvents on the activity of the extracts.

[0098] Table 1. Anti-fatigue activity test results

[0099] Grouping Exhaustive swimming time (min) Glycogen (mg / 100g liver tissue) Blank control group 7.4 1302 Positive control group 25.6 3109 AAPS-01 28.7 3225 AAPS-02 21.5 2514 L-AAPS-a 34.3 3866 L-AAPS-b 26.0 3089

[0100] Eight-week-old healthy male SD rats (weight 230-240 g) were taken and fed normally for 1 week. The vascular ED rat model was established by bilateral internal iliac artery ligation. For the sham operation group, the rats were fixed on the operating table, and a midline incision was made in the middle and lower abdomen. After opening the abdominal cavity, the bilateral internal iliac arteries were found and exposed without ligation, and then the abdominal tissue and internal organs were reset, and the peritoneum, muscles, subcutaneous fat and skin were sutured in sequence.

[0101] The rats with vascular ED were randomly divided into model group, positive control group and experimental group, with 10 rats in each group. The rats in the positive control group were given 1 mL of 0.16 mg / mL tadalafil aqueous dispersion by gavage every day, and the rats in the experimental group were given 1 mL of 20 or 60 mg / mL L-AAPS-a aqueous dispersion by gavage every day. The rats in the model group and sham operation group were not intervened, and only 1 mL of normal saline was given by gavage every day. After four weeks of continuous gavage, the penile erection was induced by stimulating the penile cavernous nerve of the rats, and the maximum intracavernous pressure ICPmax of the penis was measured using the RM6280XC multi-channel physiological signal acquisition and processing system to evaluate the erectile function of the rats. The penile cavernous nerve was stimulated twice continuously using the same method, with an interval of 10 min between the two times. The ICPmax measured after the second stimulation was used as the penile ICPmax data of the rat. The results were averaged.

[0102] The ICPmax of each group was significantly higher than that of the model group (P<0.01). The ICPmax of 60mg / mL L-AAPS-a was significantly higher than that of 20mg / mL L-AAPS-a and the positive control group, with statistically significant differences (P<0.01), proving that L-AAPS-a can improve the erectile function of model mice.

[0103] Table 2. Improvement of erectile dysfunction in animal models

[0104] Grouping ICPmax (mmHg) Sham operation group 64.5 Model Group 22.7 Positive control group 43.3 Experimental group (20 mg / mL L-AAPS-a) 34.8 Experimental group (60 mg / mL L-AAPS-a) 52.6

[0105] The extract AAPS-01 prepared as described in Example 1 was separated and purified using an InfinityLab PursuitXRs C18 Preparative HPLC Column (using acetonitrile-water gradient elution) to obtain the polypeptide AAPS-PT (SEQ ID NO: 1, amino acid sequence GTDGPHMPWEAHNILRYQDQKE), which accounted for 2.3% of the mass of the extract AAPS-01. Using the same method, the polypeptide AAPS-PT was also separated from the extract AAPS-02, which accounted for 0.5% of the mass of the extract AAPS-02.

[0106] The molecular formula of the sample is C114H168N34O36S, and elemental analysis shows that the test value is consistent with the theoretical value. ESI-MS has a main ion peak of [M+H]+2623.2, and mass spectrometry analysis shows that its ion peak is consistent with the molecular structure of AAPS-PT.

[0107] MRI test results:

[0108] 1 H NMR (400 MHz, DMSO- d6) δ 8.73-8.60 (m, 4H), 8.52 – 8.47 (m, 5H),8.32 – 8.09 (m, 17H), 7.93 (d, 1H), 7.80 (dd, 2H), 7.66 – 7.51 (m, 7H), 7.39-7.35 (m, 1H), 7.28 (s, 2H), 7.22 – 7.11 (m, 7H), 7.03 – 6.98 (m, 4H), 6.91(s, 4H), 6.78 – 6.69 (m, 2H), 5.93 (t, 2H), 4.92 (d, 1H), 4.79 – 4.56 (m,9H), 4.42 – 4.15 (m, 15H), 3.90 – 3.79 (m, 5H), 3.57 – 3.49 (m, 1H), 3.39 (m,1H), 3.27 – 3.09 (m, 4H), 2.92 – 2.68 (m, 9H), 2.60 – 2.48 (m, 7H), 2.44 –2.25 (m, 4H), 2.19 – 1.97 (m, 14H), 1.81 – 1.56 (m, 14H), 1.52 – 1.33 (m,7H), 1.25 – 1.16 (m, 7H), 0.99 – 0.61 (m, 12H)。

[0109] 13 C NMR (100 MHz, DMSO- d 6) δ179.26, 175.86, 175.54, 175.32, 174.49,174.00, 173.92, 173.80, 173.52, 173.33, 173.24, 173.02, 172.87, 172.62,172.59, 172.40, 172.26, 172.18, 172.14, 172.11, 171.96, 171.94, 171.90,171.35, 171.15, 170.97, 169.62, 160.59, 157.84, 156.78, 69.98, 68.54,67.06, 60.23, 60.14, 59.66, 58.70, 55.24, 53.92, 53.13, 53.11, 52.99, 52.94,52.70, 32.65, 31.24, 31.02,30.73, 30.55, 30.04, 29.86, 29.39, 28.97, 28.80, 28.71, 28.02, 27.65, 27.14,26.70, 26.64, 26.42, 25.85, 25.42, 24.60, 24.55, 23.40, 22.99, 19.93, 17.81,16.56, 14.56, 12.68.

[0110] Example 6. Synthesis of polypeptide

[0111] The peptide AAPS-PT was obtained by Fmoc solid phase synthesis using a peptide synthesizer (Aurora, VERSA 110). A white solid was obtained by drying; the solid was separated and purified using an InfinityLab Pursuit XRs C18 Preparative HPLC Column (using acetonitrile-water gradient elution), and freeze-dried to obtain pure AAPS-PT with an HPLC purity of 96.9%. The elemental analysis, ESI-MS, and NMR test results were all the same as those in Example 5. This proves that AAPS-PT is indeed a polypeptide with an amino acid sequence as shown in SEQ ID NO:1.

[0112] Example 7. Preparation of Preparations

[0113] Preparation Example 1: The extract AAPS-01 prepared as described in Example 1 was sterilized by irradiation, granulated, dried, and granulated to obtain composite granules. The composite granules were filled into capsule shells, with each capsule shell being filled with 200 mg of the drug, to obtain hard capsules.

[0114] Preparation Example 2: The composition L-AAPS-a prepared by the method described in Example 2 was sterilized by irradiation, granulated, dried, and granulated to obtain composition granules. The composition granules were filled into capsule shells, with each capsule shell being filled with 300 mg of the drug, to obtain hard capsules.

[0115] Preparation Example 3: The polypeptide AAPS-PT prepared as described in Example 6 was used together with lactose and mannitol in a 2% hydroxypropyl methylcellulose aqueous solution to prepare wet granules, dried at 45°C, and granulated to obtain granules. The granules were filled into capsule shells to obtain hard capsules.

[0116] Preparation Example 4: The composition L-AAPS-a prepared as described in Example 2 was irradiated and sterilized with 60Co radiation and an irradiation dose of 3 kGy; 8 g was evenly dispersed in 500 mL of sterile water; 1.9 g of β-cyclodextrin and 0.4 g of sorbic acid were added, mixed, and filled into 50 bottles of oral solution.

[0117] Preparation Example 5: The composition L-AAPS-a prepared as described in Example 2 was irradiated and sterilized with 60Co radiation at a dose of 3 kGy; 5% by weight of 70% ethanol (V / V) was added to the sterilized mixture to make a soft material, which was then granulated through a 10-16 mesh sieve; dried at 50 degrees Celsius for 4 hours; granulated to obtain composition granules, 2 g of which was taken, and 1.2 g of mannitol, 0.3 g of hydroxypropyl cellulose, 0.03 g of micro-powdered silica gel, 0.05 g of talc, and 0.04 g of magnesium stearate were added, mixed, and pressed into 10 tablets.

[0118] Preparation Example 6: The composition L-AAPS-a prepared as described in Example 2 was irradiated and sterilized with 60Co radiation at a dose of 3 kGy; 5% by weight of 70% ethanol (V / V) was added to the sterilized mixture to make a soft material, which was then granulated through a 10-16 mesh sieve; dried at 50 degrees Celsius for 4 hours; granulated to obtain composition granules, 2 g of which was taken, and 1.2 g of mannitol, 0.3 g of hydroxypropyl cellulose, 0.03 g of micro-powdered silica gel, 0.05 g of talc, and 0.04 g of magnesium stearate were added, mixed, and pressed into 300 small pellets.

[0119] Example 8. Peptide Activity Test

[0120] The anti-fatigue activity of the polypeptide AAPS-PT prepared by the method described in Example 6 was tested using exactly the same method as in Example 3, except that the extract or composition given to the mice was replaced with an equal mass of polypeptide AAPS-PT. The results showed that the exhaustive swimming time of the mice in the AAPS-PT group was 31.3 min, which was much better than the 7.1 min of the blank control group (P<0.001) and better than the 25.1 min of the positive control group (P<0.05). This shows the excellent anti-fatigue activity of the polypeptide AAPS-PT.

[0121] The erectile function test of the polypeptide AAPS-PT prepared by the method described in Example 6 was carried out using the same method as in Example 4, except that the daily oral administration of 60 mg / mL L-AAPS-a was replaced by daily oral administration of 60 mg / mL polypeptide AAPS-PT. The results showed that the ICPmax of rats in the AAPS-PT group reached 54.5 mmHg, which was much better than the 21.3 mmHg of the model group (P<0.001) and better than the 42.4min of the positive control group (P<0.01). This shows that the polypeptide AAPS-PT has an excellent effect on improving penile erectile function.

[0122] Example 9: Kidney-tonifying functional pharmacological experiment

[0123] Male SD rats weighing 95-105 g and about one month after weaning were taken and injected subcutaneously with urethane to achieve light anesthesia. The scrotal skin was disinfected with iodine and the testicles were removed. Penicillin sodium was injected intramuscularly after surgery to prevent infection. Male rats with kidney deficiency model were obtained 3 days later and the model was successfully established.

[0124] The rats were randomly divided into 10 groups: the castrated model group was given an equal volume of saline by gavage every day; the testosterone propionate group was given a subcutaneous injection of testosterone propionate at a dose of 2 mg / kg every day; the experimental group 1 was given an aqueous dispersion of L-AAPS-a at a dose of 200 mg / kg by gavage every day; the experimental group 2 was given an aqueous dispersion of polypeptide AAPS-PT at a dose of 200 mg / kg by gavage every day; and the rats from the same batch that were not castrated were taken as the normal control group. After 4 consecutive weeks of administration in each group, the rats were killed by cervical dislocation, and the preputial glands, seminal vesicles + prostate, and levator ani muscles were taken, weighed, and the organ coefficients were calculated, and the average value of each group was taken. The results are shown in Table 3. Compared with the model group, the weights of the preputial glands, seminal vesicles, prostates, and levator ani muscles in the experimental group 1 and the experimental group 2 were significantly increased, reaching statistically significant differences (P<0.01), respectively, proving that the L-AAPS-a composition and the polypeptide AAPS-PT significantly increased the organ coefficients of the reproductive organs of rats with kidney deficiency, and had a significant effect on kidney deficiency impotence.

[0125] Table 3. Results of kidney-tonifying experiment

[0126]

[0127] Although the embodiments of the present disclosure have been described above, it will be understood that the above embodiments are exemplary and do not constitute limitations to the present disclosure. Any modifications, equivalent substitutions and improvements made by ordinary technicians in the field within the spirit and principles of the present invention should be included in the scope of protection of the present invention.

Claims

1. An extract, characterized in that The preparation method of the extract comprises the following steps: Take the whole plant of Artemisia africana and the whole plant of Pelargonium sutchuenensis, wash them with water, air-dry them at room temperature, and grind them into a fine powder with an average particle size of 900 microns to obtain the fine powder of the above two plant raw materials; Take equal masses of the two fine powders and mix them to obtain a mixed powder; add an ethanol-isopropanol-water mixed solvent with a mass 10 times that of the mixed powder, wherein the volume ratio of the ethanol, isopropanol and water is 3:1:1; heat to 50° C. and stir at a rate of 100 rpm for 5 hours, filter after cooling, and freeze-dry the filtrate to obtain the extract.

2. A composition, characterized in that The preparation method of the composition comprises the following steps: Take 10-85 parts by weight of ginseng, 10-90 parts by weight of sika deer penis, 20-95 parts by weight of red deer antler, 15-90 parts by weight of sea cucumber, 20-95 parts by weight of oyster, 20-90 parts by weight of polygonatum, 25-110 parts by weight of wolfberry, 10-90 parts by weight of maca, 10-95 parts by weight of yam, 25-100 parts by weight of epimedium, 10-85 parts by weight of Cistanche deserticola, 0.5-6 parts by weight of Cordyceps militaris, 15-90 parts by weight of Eucommia ulmoides, 20-95 parts by weight of okra, 10-90 parts by weight of silkworm chrysalis, and 10-90 parts by weight of ginseng. 0 parts by weight, 25-100 parts by weight of Cuscuta seeds, 25-100 parts by weight of Rosa laevigata, 25-100 parts by weight of Acanthopanax senticosus, 25-100 parts by weight of Rhodiola rosea, 25-100 parts by weight of royal jelly, 25-95 parts by weight of pumpkin seed oil, 20-90 parts by weight of lycopene, 20-90 parts by weight of pyrroloquinoline quinone, 10-90 parts by weight of taurine, 10-95 parts by weight of gamma-aminobutyric acid, and 50 parts by weight of extracts of Artemisia africana and Pelargonium sphenanthera; mix well to obtain the composition; The preparation method of the extracts of Artemisia africana and Pelargonium sphenanthera is as described in claim 1.

3. A composition, characterized in that The preparation method of the composition comprises the following steps: Take raw sun-dried ginseng, sika deer penis, velvet antler of Northeast red deer, imitation sea cucumber, long oyster meat, rhizome of polygonatum yunnanensis, fruit of wolfberry, rhizome of maca, tuber of yam, stem and leaf of epimedium pubescens, stem of cistanche deserticola, fruiting body of cordyceps militaris, bark of eucommia bark, immature tender fruit of okra, silkworm pupa, dodder seed, rosa laevigata fruit, rhizome of acanthopanax senticosus and rhodiola rosea; wash them with water, air-dry them at room temperature, and grind them into powder with an average particle size of 900 μm to obtain powder of each raw material; Take 50g of ginseng powder, 50g of sika deer penis powder, 50g of red deer antler powder, 50g of sea cucumber powder, 50g of oyster powder, 50g of polygonatum powder, 50g of wolfberry powder, 50g of maca powder, 50g of yam powder, 50g of epimedium powder, 50g of Cistanche powder, 5g of Cordyceps militaris powder, 50g of Eucommia powder, 50g of okra powder, 50g of silkworm pupa powder, 50g of Cuscuta powder, 50g of Rosa laevigata powder, 50g of Acanthopanax powder, and 50g of Rhodiola rosea powder obtained as described above; then add 50g of worker bee royal jelly of Apis cerana cerasifera, 50g of pumpkin seed oil, 20g of lycopene, 20g of pyrroloquinoline quinone, 10g of taurine, 10g of γ-aminobutyric acid, and 50g of extracts of Artemisia africana and Pelargonium angustifolia; mix well to obtain the composition; The preparation method of the extract of Artemisia africana and Pelargonium stenosis is as follows: take the whole plant of Artemisia africana and the whole plant of Pelargonium stenosis, wash them with water respectively, air-dry them at room temperature, and grind them to an average particle size of 900 microns; take 50g of Artemisia africana powder and 50g of Pelargonium stenosis powder, mix them evenly, add 1kg of ethanol-isopropanol-water mixed solvent, and the volume ratio of ethanol, isopropanol and water is 3:1:1; heat to 50°C and stir at a rate of 100 rpm for 5 hours, filter after cooling, and freeze-dry the filtrate to obtain the extract of Artemisia africana and Pelargonium stenosis.

4. Use of the composition as claimed in claim 3 in the preparation of an anti-fatigue drug, a drug for improving erectile dysfunction or a drug for strengthening sexual function.

5. A pharmaceutical preparation, characterized in that The pharmaceutical preparation comprises the extract according to claim 1, or, the composition according to claim 2 or 3; The pharmaceutical preparation is an oral dosage form, which is a tablet, capsule, granule, pill or oral liquid.

6. A method for preparing a pharmaceutical preparation, characterized in that: The preparation method comprises the following steps: Take the composition as claimed in claim 2 or 3, sterilize it, and prepare an oral preparation using an oral dosage form process.

7. A method for preparing a pharmaceutical preparation, characterized in that: The preparation method comprises the following steps: The composition as claimed in claim 2 or 3 is sterilized by irradiation, granulated, dried and sized to obtain pharmaceutical composition granules.

8. The preparation method according to claim 7, characterized in that: The granulation method comprises adding 65%-75% ethanol in a volume fraction of 3%-6% by weight to the sterilized mixture, making a soft material and then granulating it through a 10-16 mesh sieve; The drying temperature is 50-70°C and the drying time is 2-4 hours; The irradiation sterilization environment is: cobalt-60 radiation sterilization, and the irradiation dose is greater than 0 KGY and does not exceed 6 KGY.